Literature DB >> 31401557

Longitudinal changes in the ganglion cell-inner plexiform layer thickness in high myopia: a prospective observational study.

Min Woo Lee1,2, Ki Yup Nam3, Hye Jin Park1, Hyung-Bin Lim1, Jung-Yeul Kim4.   

Abstract

AIM: To determine longitudinal changes of the ganglion cell-inner plexiform layer (GC-IPL) thickness in patients with high myopia.
METHODS: The subjects were divided into two groups: a high myopia group (axial length ≥26.0 mm) and a normal control group. Both groups were divided into subgroups based on age (decade): 20s, 30s, 40s and 50s. Twenty eyes were included in each subgroup. After the initial visit, GC-IPL thicknesses were measured three more times with at least a 1-year interval between examinations using spectral domain optical coherence tomography. The average GC-IPL thickness was fitted with linear mixed models.
RESULTS: The average GC-IPL thickness at the first visit was 78.50 ± 8.79 µm and 84.29 ± 6.12 µm in the high myopia and control groups, respectively. In both groups, the average GC-IPL thickness showed a significant change over time. The rate of GC-IPL reduction in individuals aged in their 50s, 40s, 30s and 20s with high myopia were -0.81 µm/year,-0.51 µm/year, -0.28 µm/year and -0.12 µm/year, respectively, and in controls in their 50s, 40s, 30s and 20s, they were -0.31 µm/year,-0.25 µm/year, -0.12 µm/year and -0.02 µm/year, respectively. Additionally, individuals aged in their 50s showed a statistically significant interaction between group and duration (p<0.001).
CONCLUSIONS: Highly myopic eyes had thinner GC-IPL and a significantly greater reduction in GC-IPL over 3 years when compared with normal eyes. Additionally, the reduction rate of the GC-IPL thickness was greater in older patients in both groups, which was more prominent in the high myopia group. © Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  ganglion cell-inner plexiform layer; high myopia; spectral domain optical coherence tomography

Year:  2019        PMID: 31401557     DOI: 10.1136/bjophthalmol-2019-314537

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  6 in total

1.  Peripapillary Retinal Nerve Fiber Layer and Microvasculature in Prolonged Type 2 Diabetes Patients Without Clinical Diabetic Retinopathy.

Authors:  Min-Woo Lee; Woo-Hyuk Lee; Cheon-Kuk Ryu; Yong-Min Lee; Young-Hoon Lee; Jung-Yeul Kim
Journal:  Invest Ophthalmol Vis Sci       Date:  2021-02-01       Impact factor: 4.799

2.  Optic Atrophy and Inner Retinal Thinning in CACNA1F-related Congenital Stationary Night Blindness.

Authors:  Kate E Leahy; Tom Wright; Monika K Grudzinska Pechhacker; Isabelle Audo; Anupreet Tumber; Erika Tavares; Heather MacDonald; Jeff Locke; Cynthia VandenHoven; Christina Zeitz; Elise Heon; J Raymond Buncic; Ajoy Vincent
Journal:  Genes (Basel)       Date:  2021-02-25       Impact factor: 4.096

3.  Longitudinal Changes in Peripapillary Retinal Nerve Fiber Layer and Macular Ganglion Cell Inner Plexiform Layer in Progressive Myopia and Glaucoma Among Adolescents.

Authors:  Hui Xiao; Yimin Zhong; Yunlan Ling; Xiaoyu Xu; Xing Liu
Journal:  Front Med (Lausanne)       Date:  2022-03-22

4.  Assessment of macular structures and vascular characteristics in highly myopic anisometropia using swept-source optical coherence tomography angiography.

Authors:  Xin Wang; Yanhui Chen; Zhiyang Wang; Haoru Li; Qing He; Hua Rong; Ruihua Wei
Journal:  Front Physiol       Date:  2022-08-15       Impact factor: 4.755

5.  Defective Temporal Window of the Foveal Visual Processing in High Myopia.

Authors:  Haiyan Zheng; Xiaoxiao Ying; Xianghang He; Jia Qu; Fang Hou
Journal:  Invest Ophthalmol Vis Sci       Date:  2021-07-01       Impact factor: 4.799

6.  Association of high myopia with peripapillary retinal nerve fiber layer in patients with hypertension.

Authors:  Min-Woo Lee; Hyung-Bin Lim; Hyung-Moon Koo; Young-Hoon Lee; Jung-Yeul Kim
Journal:  PLoS One       Date:  2021-08-13       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.